Cancer Center Program Memberships

Research Summary

I am a widely recognized researcher with a reputation for identifying and pursuing high-impact questions that make practical contributions to tobacco control policy development, evaluation, and implementation. I am skilled in both qualitative and quantitative research methods, having written several books on tobacco control policy and two successful statistics textbooks. As Director of the UCSF Center for Tobacco Control Research and Education (CTCRE), I have extensive practical experience in developing and managing transdisciplinary academic programs and bringing together faculty from many disciplines. I have supervised a total of 96 fellows and graduate students during my career and am the Program Director of the CTCRE Postdoctoral Training Program in collaboration with Dr. Pamela Ling. I have published in a broad range of tobacco control areas, including economic models of the effects of tobacco control policies on health outcomes and health care costs, social and environmental determinants of smoking and smoking cessation, young adult smoking, and health effects of secondhand smoke, particularly on heart disease. I wrote the first papers based on analyses of previously secret tobacco industry documents (published in JAMA in 1995). Since then, I have worked with the UCSF Library to build the Legacy Tobacco Documents Library, which now exceeds 83 million pages (and is growing). The library is a major international research resource that has supported preparation of over 900 publications, including 134 authored by me, and the CTCRE is an internationally known training resource for tobacco document research that serves postdoctoral fellows and many others working in tobacco control. I am also the Principal Investigator of the UCSF Tobacco Center of Regulatory Science (TCORS), which brings together a broad multidisciplinary group of faculty and provides training opportunities and funds for pilot studies for trainees with an interest in tobacco regulatory science.

Glantz SA. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Tob Control. 2018 Nov; 27(Suppl 1):s9-s12.View on PubMed